CRRT for AKI during COVID-19 Pandemic

medcases00
Published on Jul 23, 2021
Video EMBED original source - NUGoKidney - Dr. ASHITA TOLWANI
https://www.youtube.com/channel/UC-FSzemwuWaS9zsr5KgqidQ/videos
SUBSCRIBE: http://bit.ly/2uY2BEd

How might CRRT prescription need to be adjusted for patients with acute kidney injury (AKI)and COVID-19?

Ashita Tolwani, MD from the University of Alabama at Birmingham explains how CRRT prescription might need to be adjusted in regards to modality, dose, and anticoagulation for AKI patients with COVID-19.

Ashita Tolwani, MD, MSc, is Professor of Medicine at the University of Alabama at Birmingham (UAB). Dr. Tolwani was the Nephrology Fellowship Training Program Director from 2002 to 2010 and is now the Associate Program Director. She completed her nephrology fellowship at UAB and joined the Division as a faculty member in 1999. Her interests are in clinical outcomes research in acute kidney injury and continuous renal replacement therapy. She received a Masters of Science in Clinical Epidemiology from the Harvard School of Public Health in June 2004. She heads the CRRT Program at UAB and organizes an annual UAB CRRT Academy for trainees, practicing physicians, and nursing from across the United States.

___________________________________________________________________

About NUGoKidney
Northwestern University's George M. O'Brien Kidney Research Core Center provides data, tools, and resources to promote collaborative partnerships and propel the development of transformative therapeutics for patients with kidney diseases.

Connect with NUGoKidney:
Sign up for NUGoKidney email newsletter: http://bit.ly/NUGoKidneyNews
Visit the NUGoKidney website: http://www.nephrohub.org/
Follow NUGoKidney on Twitter: https://twitter.com/NU_Nephrology
Follow NUGoKidney on Instagram: https://www.instagram.com/nu_nephrology/
SUBSCRIBE: http://bit.ly/2uY2BEd

How might CRRT prescription need to be adjusted for patients with acute kidney injury (AKI)and COVID-19?

Ashita Tolwani, MD from the University of Alabama at Birmingham explains how CRRT prescription might need to be adjusted in regards to modality, dose, and anticoagulation for AKI patients with COVID-19.

Ashita Tolwani, MD, MSc, is Professor of Medicine at the University of Alabama at Birmingham (UAB). Dr. Tolwani was the Nephrology Fellowship Training Program Director from 2002 to 2010 and is now the Associate Program Director. She completed her nephrology fellowship at UAB and joined the Division as a faculty member in 1999. Her interests are in clinical outcomes research in acute kidney injury and continuous renal replacement therapy. She received a Masters of Science in Clinical Epidemiology from the Harvard School of Public Health in June 2004. She heads the CRRT Program at UAB and organizes an annual UAB CRRT Academy for trainees, practicing physicians, and nursing from across the United States.

___________________________________________________________________

About NUGoKidney
Northwestern University's George M. O'Brien Kidney Research Core Center provides data, tools, and resources to promote collaborative partnerships and propel the development of transformative therapeutics for patients with kidney diseases.

Connect with NUGoKidney:
Sign up for NUGoKidney email newsletter: http://bit.ly/NUGoKidneyNews
Visit the NUGoKidney website: http://www.nephrohub.org/
Follow NUGoKidney on Twitter: https://twitter.com/NU_Nephrology
Follow NUGoKidney on Instagram: https://www.instagram.com/nu_nephrology/